AquADEK ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
299Cystic fibrosis2

299. Cystic fibrosis


Clinical trials : 1,696 Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01859390
(ClinicalTrials.gov)
June 201317/5/2013Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic FibrosisA Multi-Center, Randomized, Controlled, Double-Blind Study of the Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis PatientsCystic FibrosisDrug: AquADEKs-2;Dietary Supplement: control multivitaminUniversity of Colorado, DenverCystic Fibrosis Foundation Therapeutics;Yasoo HealthCompleted10 YearsN/AAll73Phase 2United States
2NCT01018303
(ClinicalTrials.gov)
August 200719/11/2009Safety and Efficacy of an Antioxidant-rich Multivitamin Supplement in Cystic FibrosisSafety and Efficacy of a Novel Antioxidant-rich Multivitamin Supplement for Persons With Cystic FibrosisCystic FibrosisDietary Supplement: AquADEKUniversity of Colorado, DenverCystic Fibrosis Foundation Therapeutics;Yasoo Health;National Institutes of Health (NIH)Completed10 Years40 YearsBoth17Phase 1/Phase 2United States